Actavis brokered deal to maintain high hydrocortisone prices

A government watchdog has alleged that manufacturers Actavis UK and Concordia worked together to artificially maintain an inflated price for hydrocortisone tablets.

actavis_logo_620x413px.jpg
Actavis UK remained sole supplier of hydrocortisone tablets until 2015

According to a Competition and Markets Authority (CMA) investigation, between January 2013 and June 2016 the two companies agreed that Concordia (formerly Amdipharm) would not enter the market with its own version of hydrocortisone tablets.

Free to registered users

Register to gain full access to C+D and C+D Community content

Sign in or register for free

Latest from News

Sebco coal tar scalp ointment appointed by DHSC to support current shortages

 • comment

Due to shortages in coal tar scalp ointment, the DHSC has asked the manufacturer of an equivalent product - Sebco - to provide increased stock levels to support patients during this time.

Pharmacies to boost naloxone stock amid ‘sudden’ overdose spike

 
• By 
 • comment

Pharmacies in Scotland have been asked to ensure they have the “appropriate stock” of naloxone – a medicine used to reverse the effects of an opiate overdose – following an “increase in sudden collapse” due to overdoses.

Cuts and commissioning: What does NHSE’s axing mean for ICBs?

 
• By 
 • comment

As the dust settles on the announcement that NHS England (NHSE) is set for the scrapheap, questions on what a 50% headcount cut means for local commissioners remain…

More from Regulation